InSnip Pure Signal, No Noise
✓ Source-backedScience & Systems
Australian biotech Neurizon advances its ALS trial with new funding
The HEALEY ALS Platform Trial is fully enrolled, with topline results now due in late Q4 FY27.
Why it mattersThe result timing is clearer, and the extra funding reduces near-term cash pressure.
Free. Be genuinely informed in 5 minutes a day. No signup, no noise.
Get the free app, read the whole feed
InSnip turns the day's news into short, source-backed snippets with a plain why it matters line. The signal, not the scroll.